Novel GLP1R agonist with enhanced ВВВ permeability for the treatment of neurodegenerative diseases
Alzheimer's disease (AD) is a neurocognitive disorder and the most common cause of dementia.
Published literature postulates that a GLP-1 agonist may offer a protective effect through the insulinotrophic mechanism, Akt activation, inhibition of microglial activation, improved mitochondrial function due to PGC-1α induction, increased neurogenesis, or increased production trophic factors. GLP1 agonists have shown to potentially inhibit microglial activation via GLP1 receptors.
AVVA is at the stage of development and testing a new long acting GLP-1 receptor agonist with high blood-brain barrier permeability potential for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD).
Roman G. Efremov
Professor, Doctor of Science
Deputy sci-director (Direction), Principal research fellow (Laboratory of biomolecular modeling), Leading research fellow (Group of spectral analysis) at the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
Vasily N. Stepanenko, PhD
Head of Pilot Biotech Production at the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry